Literature DB >> 9160658

Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

C M Niemeyer1, M Arico, G Basso, A Biondi, A Cantu Rajnoldi, U Creutzig, O Haas, J Harbott, H Hasle, G Kerndrup, F Locatelli, G Mann, B Stollmann-Gibbels, E T van't Veer-Korthof, E van Wering, M Zimmermann.   

Abstract

Chronic myelomonocytic leukemia (CMML) is a rare hematopoietic malignancy of childhood. To define the clinical and hematologic characteristics of the disease, we performed a retrospective analysis of 110 children given the diagnosis CMML irrespective of karyotype. Median age at diagnosis was 1.8 years. Neurofibromatosis type 1 was known in 14% and other clinical abnormalities in 7% of the children. At presentation, the medium white blood count was 35 x 10(9)/L, with a median monocyte count of 7 x 10(9)/L. Karyotypic abnormalities in bone marrow cells were noted in 36% of the patients, whereas 26% of the children had monosomy 7. Children with monosomy 7 did not differ from those with normal karyotype with respect to their clinical presentation. However, they did display some characteristic hematologic features. Of 110 children, 38 received an allogeneic bone marrow transplant (BMT). The probability of survival at 10 years was 0.39 (standard error [SE] = 0.10) for the BMT group and 0.06 (SE = 0.4) for the 72 patients of the non-BMT group. Platelet count, age, and hemoglobin F at diagnosis were the main predicting factors for the length of survival in the non-BMT group. There is a strong need for a broad agreement on nomenclature in children with myelodysplastic syndromes (MDS). We propose here to use the French-American-British classification for MDS in childhood.

Entities:  

Mesh:

Year:  1997        PMID: 9160658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  101 in total

1.  Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Camille B Troup; Laura C Gelston; John Haliburton; Eric D Chow; Kristie B Yu; Jon Akutagawa; Amaro N Taylor-Weiner; Y Lucy Liu; Yong-Dong Wang; Kyle Beckman; Peter D Emanuel; Benjamin S Braun; Adam Abate; Robert B Gerbing; Todd A Alonzo; Mignon L Loh
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.

Authors:  Sarah Abu Kar; Anna Jankowska; Hideki Makishima; Valeria Visconte; Andres Jerez; Yuka Sugimoto; Hideki Muramatsu; Fabiola Traina; Manuel Afable; Kathryn Guinta; Ramon V Tiu; Bartlomiej Przychodzen; Hirotoshi Sakaguchi; Seiji Kojima; Mikkael A Sekeres; Alan F List; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 3.  JMML genomics and decisions.

Authors:  Charlotte M Niemeyer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  [Tumor necrosis factor-α and transforming growth factor-β1 balance liver stem cell differentiation in cholestatic cirrhosis].

Authors:  Bo Yang; Qing Luo; Quan Kang; Jian Wang; Cheng Xiao; Zhi-Peng Li; Meng-Jia Gong; Yang Bi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

5.  Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.

Authors:  Michiko Muraoka; Chiho Okuma; Kiichiro Kanamitsu; Hisashi Ishida; Yui Kanazawa; Kana Washio; Masafumi Seki; Motohiro Kato; Junko Takita; Yusuke Sato; Seishi Ogawa; Hirokazu Tsukahara; Megumi Oda; Akira Shimada
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

6.  Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.

Authors:  Anand Pathak; Alexander Pemov; Mary L McMaster; Ramita Dewan; Sarangan Ravichandran; Evgenia Pak; Amalia Dutra; Hyo Jung Lee; Aurelie Vogt; Xijun Zhang; Meredith Yeager; Stacie Anderson; Martha Kirby; Neil Caporaso; Mark H Greene; Lynn R Goldin; Douglas R Stewart
Journal:  Hum Genet       Date:  2015-05-05       Impact factor: 4.132

7.  Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation.

Authors:  Christian Peter Kratz; Michaela Nathrath; Peter Freisinger; Petra Dressel; Hans-Peter Assmuss; Cornelia Klein; Ayami Yoshimi; Stefan Burdach; Charlotte Marie Niemeyer
Journal:  Eur J Pediatr       Date:  2005-12-21       Impact factor: 3.183

8.  Molecular basis of juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; C Michael Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

9.  Granulocytic sarcoma presenting with severe adenopathy (cervical lymph nodes, tonsils, and adenoids) in a child with juvenile myelomonocytic leukemia and successful treatment with allogeneic bone marrow transplantation.

Authors:  Toshihiko Imamura; Satoshi Matsuo; Takao Yoshihara; Tomohiro Chiyonobu; Kanako Mori; Hiroyuki Ishida; Yasutaka Nishimura; Yasuo Kasubuchi; Mayumi Naya; Akira Morimoto; Shigeyoshi Hibi; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

10.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.